etronidazole, a nitroimidazole that has been on the U.S. market since 1961, is used to treat trichomoniasis, bacterial vaginosis (BV), amebiasis, giardiasis, and numerous anaerobic bacterial infections. It has been shown to cause cancer in mice and rats (but not in other species) and to be mutagenic in some bacterial systems and even embryotoxic in some in vitro tests. 1,z The relevance of these studies to humans is questionable. This paper reviews available human data and some animal studies that examine the potential for teratogenicity in humans.
HUMAN STUDIES
In a study of women undergoing therapeutic abortion, Heisterberg 3 showed that metronidazole crossed the placental membrane; placental concentrations were approximately 50-65% of those in maternal plasma. Amon and Amon 4 found that, on occasion, the fetal metronidazole tissue concentrations exceeded those found in maternal plasma. No controlled clinical trials have been conducted specifically to determine whether metronidazole is teratogenic in humans. However, numerous reports have been published in which the effects of metronidazole taken to treat an infection during pregnancy were examined. Tables 1-3 give a synopsis of findings in pregnant women. The larger studies are briefly summarized below.
Rosa et al. s used a large health management organization's database including 104,339 women who gave birth to normal children and 6,564 women who delivered babies with anomalies. These included 1,083 women treated with metronidazole in the first trimester. Of these babies, 1,020 were normal and 63 were born with some anomaly; the relative risk of an anomaly being associated with metronidazole treatment in this cohort was 0.92. These authors reported an increased risk of spontaneous abortion in patients prescribed metronidazole in the 120-day period prior to spon- [7] 31 31 31 4 (50282) (50282) (3248) Piper, et al [8] [I 6] Polydactyly (familial) Kotcher [21] Crooked foot Zacharias [18] Rh factor (stillborn) Cant6 [30] Midline facial defects (I) Tables 1, 2, and 3. Other studies, summarized in Table 1 , have reported results that allowed similar conclusions to be drawn. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Summarizing these 37 studies (which include three case reports of defects in offspring of metronidazole-treated mothers3'4), 5 ,333 mothers were treated with metronidazole during pregnancy, and 5,369 infants were born to these mothers. Two hundred eleven major and minor malformations (3.93%) were recorded. These included some infants with defects which were obviously genetic (Rh incompatibility, mental retardation in an infant born to retarded parents, familial polydactyly, Down's syndrome). One hundred eighty-nine infants (3.52%) were aborted, stillborn, or died very early in the postnatal period. Deaths included three infants from a group of seven pregnant women treated with metronidazole for amebic, pyogenic, or mixed hepatic abscess; two of the mothers died from the abscess as well. z4 If only studies including controls are considered, s-l,zz 3,765 mothers who gave birth to 3,788 infants were treated with metronidazole; 181 infants (4.77%) had congenital defects. This compares favorably with the 10,071 defects in 166,201 control infants examined (6.06% congenital anomalies).
Both the spectrum and incidence of defects reported in infants born to metronidazole-treated mothers approximates that which one would expect in any large group of infants. In those studies that included a control group, the incidence or relative risk of defects with metronidazole treatment was similar to that found in controls.
Burtin et al. 44 have published a metaanalysis in which the safety of metronidazole in pregnancy was reviewed, using seven appropriately controlled studies, s-7,11,1e,3s, 4 The odds ratio for teratogenesis with vs. without metronidazole was 1 Metronidazole ("trichomonacide," stated to be identical to the French product Flagyl) was reported in a Bulgarian study to cause embryotoxic and teratogenic effects in rats, mice, and guinea pigs at dose levels corresponding to the human dose.
sl The period that the drug was administered was apparently the third trimester of pregnancy. Problems with abortions were experienced in both treated and untreated groups of guinea pigs but were more frequent in the metronidazole group. Birth defects (type unspecified) were reported in two out of five young in the treated group and three out of 26 young in the control group. In mice, "birth defects" were increased and viability somewhat decreased in the metronidazole-treated group. The rat studies were complicated by cannibalism of "a majority" of newborns in both treated and control groups. The paucity of data in the paper and the large number of deaths in both treated and control groups of all three species used make these results difficult to interpret, sl Giknis and Damjanov se reported fetotoxicity and teratogenicity in mice treated concomitantly with metronidazole and high doses of ethanol and "mild fetotoxicity" with metronidazole alone.
Treatment was given on days 8, 10, 12, and 14. The route of administration of both metronidazole and ethanol used was intraperitoneal. Intraperitoneal dosing of any drug to pregnant mice presents onerous mechanical problems. In the process of four injections each in 53 pregnant mice, whose wiggling uterine horns fill the abdomen, occasional intrauterine injection is nearly impossible to avoid. That is, the actual route of administration of drug in this study may have been intrauterine in some cases, rather than intraperitoneal. The median lethal does (LDs0) of ethanol has been reported to be 7.8 g/kg. A recent publication of results of a large multicentered study (13, 816 women) by Cotch et al. 67 showed that both BV and trichomoniasis at midgestation increased the risk of low birth weight and preterm delivery. Compared with uninfected women, women with both infections had a substantially higher incidence of low birth weight (13 
